Exact Sciences Co. (NASDAQ:EXAS) Shares Bought by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. lifted its position in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 37.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 37,286 shares of the medical research company's stock after purchasing an additional 10,165 shares during the quarter. Robeco Institutional Asset Management B.V.'s holdings in Exact Sciences were worth $2,095,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Chicago Partners Investment Group LLC boosted its position in shares of Exact Sciences by 1.7% during the third quarter. Chicago Partners Investment Group LLC now owns 9,261 shares of the medical research company's stock worth $651,000 after buying an additional 158 shares during the period. Perigon Wealth Management LLC lifted its stake in Exact Sciences by 3.2% during the fourth quarter. Perigon Wealth Management LLC now owns 8,436 shares of the medical research company's stock worth $474,000 after purchasing an additional 264 shares during the last quarter. Huntington National Bank boosted its holdings in shares of Exact Sciences by 838.1% in the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company's stock valued at $27,000 after buying an additional 352 shares in the last quarter. CIBC Asset Management Inc grew its holdings in shares of Exact Sciences by 6.1% during the third quarter. CIBC Asset Management Inc now owns 6,489 shares of the medical research company's stock worth $442,000 after purchasing an additional 371 shares during the last quarter. Finally, Advisors Asset Management Inc. raised its position in Exact Sciences by 1.4% in the 3rd quarter. Advisors Asset Management Inc. now owns 28,650 shares of the medical research company's stock valued at $1,952,000 after purchasing an additional 402 shares during the last quarter. Institutional investors and hedge funds own 88.82% of the company's stock.

Insider Buying and Selling at Exact Sciences

In other Exact Sciences news, CEO Kevin T. Conroy purchased 19,500 shares of Exact Sciences stock in a transaction dated Wednesday, November 13th. The stock was acquired at an average price of $51.35 per share, for a total transaction of $1,001,325.00. Following the acquisition, the chief executive officer now owns 1,074,191 shares in the company, valued at $55,159,707.85. This trade represents a 1.85 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.36% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. The Goldman Sachs Group decreased their price objective on Exact Sciences from $75.00 to $65.00 and set a "buy" rating on the stock in a research note on Wednesday, November 6th. TD Cowen boosted their target price on Exact Sciences from $82.00 to $86.00 and gave the stock a "buy" rating in a report on Tuesday, November 26th. Sanford C. Bernstein boosted their price target on Exact Sciences from $75.00 to $90.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 30th. Craig Hallum reduced their target price on Exact Sciences from $82.00 to $65.00 and set a "buy" rating for the company in a research note on Wednesday, November 6th. Finally, Canaccord Genuity Group dropped their target price on shares of Exact Sciences from $95.00 to $75.00 and set a "buy" rating on the stock in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat, Exact Sciences presently has a consensus rating of "Moderate Buy" and an average target price of $72.76.

Exact Sciences Trading Down 1.4 %

Exact Sciences stock traded down $0.75 during trading hours on Friday, reaching $53.53. The company had a trading volume of 1,716,717 shares, compared to its average volume of 2,221,293. Exact Sciences Co. has a 12-month low of $40.62 and a 12-month high of $79.62. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.12 and a quick ratio of 1.93. The company has a 50-day moving average price of $57.31 and a 200 day moving average price of $59.97. The firm has a market cap of $9.91 billion, a price-to-earnings ratio of -45.75 and a beta of 1.24.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The medical research company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01). The company had revenue of $708.66 million during the quarter, compared to the consensus estimate of $716.80 million. Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The company's revenue was up 12.8% compared to the same quarter last year. Equities analysts forecast that Exact Sciences Co. will post -1.1 earnings per share for the current year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.